Double-blind clinical trial for evaluating the effectiveness and tolerability of Ageratina pichinchensis extract on patients with mild to moderate onychomycosis. A comparative study with ciclopirox

Planta Medica

Volumn 74, Issue 12, 2008, Pages 1430-1435

  Romero Cerecero, Ofelia ^a,b   Zamilpa, Alejandro ^a   Jiménez Ferrer, Jesús Enrique ^a   Rojas Bribiesca, Gabriela ^a   Román Ramos, Rubén ^b   Tortoriello, Jaime ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSIDAD AUTÓNOMA METROPOLITANA   (Mexico)

Author keywords

Ageratina pichinchensis; Asteraceae; Dermatomycosis; Encecalin; Onychomycosis; Topic lacquer solution

Indexed keywords

AGERATINA PICHINCHENSIS EXTRACT; CICLOPIROX; PAINT; PLANT EXTRACT; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGERATINA; AGERATINA PICHINCHENSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MEXICO; ONYCHOMYCOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TRICHOPHYTON RUBRUM;

ADMINISTRATION, TOPICAL; ADULT; AGERATINA; ANTIFUNGAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; ONYCHOMYCOSIS; PHYTOTHERAPY; PLANT EXTRACTS; TREATMENT OUTCOME;

AGERATINA; ARTHRODERMATACEAE; ASTERACEAE;

EID: 54249120536     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1081338     Document Type: Article

References (26)

1. Rzedowski J, De Rzedowski GC. Flora fanerogámica del valle de México, 1st edition. México: Instituto de Ecología: Escuela Nacional de Ciencias Biológicas del Instituto Politécnico Nacional; 1985: 454
2. Argueta A, Cano L, Rodarte M. Atlas de la medicina tradicional Mexicana. Tomos 1-3. México, D.F: Instituto Nacional Indigenista; 1994: 1786
3. Avilés M, Suárez G. Catálogo de plantas medicinales jardín etnobotánico. México: Cuernavaca, Morelos, : Centro INAH; 1994: 47
4. Monroy-Ortiz C, Castillo-España P. Plantas medicinales utilizadas en Morelos. México: Centro de Investigaciones Biológicas Universidad Autónoma del Estado de Morelos; 2000: 61-2
5. Gómez F, Quijano L, Calderón JS, Perales A, Ríos T. 2, 2-Dimethylcromenes from Eupatorium aschembornianum. Phytochemistry 1982; 21: 2095-7
6. Navarro VM, García A, González M, Fuentes A, Avilés M, Ríos Y et al. Antifungal activities of nine traditional Mexican medicinal plants. J Ethnopharmacol 2003; 87: 85-8
7. Ríos MY, Aguilar-Guadarrama B, Navarro VM. Two new benzofuranes from Eupatorium aschenbornianum and their antimicrobial activity. Planta Med 2003; 69: 967-70
8. Castañeda P, Gómez L, Mata R. Phytogrowth-inhibitory and antifungal constituents of Helianthella quinquenervis. J Nat Prod 1996; 59: 323-6
9. Romero-Cerecero O, Rojas G, Navarro V, Herrera-Arellano H, Zamilpa-Álvarez A, Tortoriello J. Effectiveness and tolerability of a standardized extract from Ageratina pichinchensis on patients with tinea pedis. A double blind clinical trial. Planta Med 2006; 72: 1257-61
10. Gupta AK, Joseph WS. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenail in the United States. J Am Podiat Med Assoc 2000; 90: 495-501
11. Ratnavel RC, Squire RA, Boorman GC. Clinical efficacies of shampoos containing ciclopirox olamine (1.5%) and ketoconazole (2.0%) in the treatment of seborrhoeic dermatitis. J Dermatolog Treat 2007; 18: 88-96
12. Brenner MA, Harkless LB, Mendicino RW, Page JC. Ciclopirox 8% nail lacquer topical solution for the treatment of onychomycosis in patients with diabetes: a multicenter, open-label study. J Am Podiat Med Assoc 2007; 97: 195-202
13. Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol 2000; 43: S70-S80
14. Sidou F, Soto P. A randomized comparison of nail surface remanence of three nail lacquers, containing amorfiline 5%, ciclopirox 8% or triconazole 28%, in healthy volunteers. Int J Tissue React 2004; 26: 17-24
15. Arenas R. Dermatophytoses in Mexico. Rev Iberoam Micol 2002; 19: 63-7
16. Madhuri JT, Raghu RR, Joga LD, Ratna KG. Onychomycosis: a significant medical problem. Indian J Dermatol 2002; 68: 326-9
17. Campbell AW, Anyanwu EC, Morad M. Evaluation of the drug treatment and persistence of onychomycosis. Sci World J 2004; 4: 60-77
18. Cedeño L, Vázquez del Mercado E, Arenas R. Onicomicosis en pacientes geriátricos. Dermatología cosmética, médica y quirúrgica. Available at http://dcmq.com.mx; Accessed 2005.
19. Finch JJ, Warshaw EM. Toenail onychomycosis: current and future treatment options. Dermatol Ther 2007; 20: 31-46
20. Albert SF, Weis ZH. Management of onychomycosis with topicals. Clin Podiat Med Surg 2004; 21: 605-15
21. Shemer A, Trau H, Davidovici B, Grunwald MH, Amichai B. Nail sampling in onychomycosis: comparative study of curettage from three sites of the infected nail. Dtsch Dermatol Ges 2007; 5: 1108-11
22. Einarson TR, Gupta AK, Shear NH, Arikan S. Clinical and economic factors in the treatment of onychomycosis. Pharmacoeconomics 1996; 9: 307-20
23. Llambrich A, Lecha M. Tratamiento actual de la onicomicosis. Rev Iberoam Micol 2002; 19: 127-9
24. Gupta AK, Lynde CW, Barber K. Pharmacoeconomic assessment of ciclopirox topical solution, 8%, oral terbinafine, and oral itraconazole for onychomycosis. J Cutan Med Surg 2006; 10 2: S54-62
25. Avner S, Nir N, Henri T. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis. Dermatol Treat 2005; 16: 327-30
26. Baran R, Gupta AK, Pierard GE. Pharmacotherapy of onychomycosis. Expert Opin Pharmacother2005; 6: 609-24